BioTech guy. Ex-BigPharma. Father, husband, sailboat racer & guitar aficionado. Tweets are mine.
Cambridge, MA
Joined March 2015
- Tweets850
- Following530
- Followers1.9K
- Likes3.3K
Don Nicholson retweeted
Today we reached another exciting clinical milestone, announcing positive data from a Phase Ib/IIa #cardiovascular (CV) risk study of lead #NLRP3 #inflammasone inhibitor candidate, NT-0796.
For more: nodthera.com/news/nodtheras-…
#Neuroinflammation #DrugDiscovery #obesity
Don Nicholson retweeted
We are pleased to announce that the first patients have been dosed in a Phase Ib/IIa #cardiovascular risk study to assess the impact of NT-0796 on cardio-metabolic biomarkers and #neuroinflammation.
For more: nodthera.com/news/nodthera-a…
#NLRP3
Don Nicholson retweeted
On Thursday, Joanne Kotz, Ph.D., Co-Founder & CEO, and Doug Pagan, CFO and COO, kick off Jnana’s fall investor conference calendar during a fireside chat at 1:50 p.m. at @Citi’s 18th Annual BioPharma Conference. ow.ly/f5XB50PIgIX #drugdiscovery #biotechnology
Don Nicholson retweeted
NodThera Looks To Compete In Long-Awaited Inflammasome Field With Parkinson’s Therapy
bit.ly/42PtOTv #PharmaScrip
Very cool clinical proof of mechanism: inhibition of SLC6A19-mediated re-uptake of phenylalanine in the kidney. JNT-517 modulates a novel, cryptic allosteric site to do so.
Today, we reported positive topline results from our Phase 1a clinical study of JNT-517, a potential first-in-class oral treatment for #PKU. JNT-517 demonstrated proof of mechanism and was safe and well tolerated. The Phase 1b is now open for enrollment. ow.ly/3Swq50OAIW3
Don Nicholson retweeted
We are thrilled to be working with fantastic colleagues at Roche to leverage our RAPID platform to advance programs targeting challenging-to-drug targets, including this immune protein-protein interaction.
jnanatx.com/jnana-therapeuti…
Don Nicholson retweeted
Moderna and @generationbio announced today that the two companies have entered into a strategic collaboration to combine Moderna’s biological and technical expertise with core technologies of Generation Bio’s non-viral #genetic medicine platform. The collaboration aims to expand the application of each company’s platform by developing novel nucleic acid therapeutics, including those capable of reaching immune cells, to accelerate their respective pipelines of non-viral genetic #medicines.
Read more: investors.modernatx.com/news…
Exciting year ahead for @DiscMedicine. Excellent article from @endpts on today's news:
With a year full of readouts ahead, Disc Medicine secures cash from Bain Capital - endpts.com/disc-medicine-sec…
Don Nicholson retweeted
We are delighted to announce a $62.5 million financing, led by @BainCapital. This investment adds to our financial strength during an exciting year for Disc as we look towards multiple data readouts and trial initiations across our #hematology portfolio. globenewswire.com/news-relea…
Don Nicholson retweeted
Disc is excited to announce a licensing agreement with Mabwell Therapeutics for novel investigational anti-#TMPRSS6 antibodies, including phase 1-ready MWTX-003, which will expand our portfolio of programs to control #iron homeostasis!
Read more here: globenewswire.com/news-relea…
Don Nicholson retweeted
Today we announced Disc has completed its merger with Gemini Therapeutics. The combined company, advancing Disc’s pipeline of hematology programs, will commence trading under the ticker symbol $IRON
Read more: globenewswire.com/news-relea…
Thanks Abbas. @AbbasRKazimi It takes a village...
So much credit & a big 'thank you' to @DonWNicholson for driving us to go after the JH2/allosteric domain of TYK2 as he always said “TYK2 is the most elegant and genetically validated drug target for I&I diseases" bit.ly/3FD3YZ4
👇
Today, we shared positive clinical data from our KT-474 Phase 1 hidradenitis suppurativa and atopic dermatitis patient cohort, as well as updates on our three oncology programs, KT-413, KT-333 and KT-253. For more information, please visit: bit.ly/3HwYOAE
Thanks @JebKeiper ! You are a class act.
Congrats to @LifeSciVC as well, who co-founded this company and was first CEO and continues to serve as Chair. Big thanks as well to my mentor @DonWNicholson who proceeded me as CEO and was a staunch supporter of pivoting to the allosteric pocket of TYK2.
Outstanding. Congrats to everyone involved. Quite frankly, it's just the start of what this remarkable molecule will do.
Today @TakedaPharma and Nimbus announced a definitive agreement under which Takeda will acquire Nimbus’ highly selective, allosteric TYK2 inhibitor: bit.ly/3VUPM4C
Splendid clinical progress from the team at @NimbusTx
We are thrilled to announce positive topline results from a Phase 2b trial evaluating our highly selective, allosteric TYK2 inhibitor NDI-034858 in patients with moderate-to-severe plaque psoriasis. bit.ly/3XHaEh7
